Pharma company pairs with RNA interference specialist
Alynylam Pharmaceuticals is strengthening its knowledge of RNA interference (RNAi) and transfection thanks to a new alliance it has formed with a specialist in solutions for intracellular delivery of nucleic acids.
Alynylam Pharmaceuticals is strengthening its knowledge of RNA interference (RNAi) and transfection thanks to a new alliance it has formed with a specialist in solutions for intracellular delivery of nucleic acids.
The collaborative agreement will see Alnylam harnessing RNAi therapeutic delivery solutions from Poylplus-transfection.
The companies believe the collaboration has the potential to bring about improvements in the delivery of siRNA therapies.
"A big advantage of this relationship is that Polyplus-transfection will benefit from having its chemical carriers tested in several disease models while working with the most advanced target sequences and mixed chemical siRNA modifications from Alnylam."
Poluplus-transfection is developing several in vivo siRNA formulation solutions based on its lead compounds in vivo-jetPEI and INTERFERin, as well as on an original RNA modification, sticky siRNA.